RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease

This study has been terminated.
Sponsor:
Information provided by:
Repligen Corporation
ClinicalTrials.gov Identifier:
NCT00060515
First received: May 7, 2003
Last updated: August 4, 2005
Last verified: August 2005

May 7, 2003
August 4, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00060515 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
RG2133 (2',3',5'-Tri-O-Acetyluridine) in Mitochondrial Disease
An Open-Label Dose-Escalation Phase I Study to Asses the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RG2133 (2',3',5'-Tri-O-Acetyluridine) in the Treatment of Inherited Mitochondrial Diseases

The objective of the study is to determine the safety and tolerability of RG2133 in patients with Mitochondrial Disease.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Primary Purpose: Treatment
Mitochondrial Diseases
Drug: RG2133 (2',3',5'-tri-O-acetyluridine)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
12
Not Provided
Not Provided

Mitochondrial Disease

Both
3 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00060515
RG2133-01
Not Provided
Not Provided
Repligen Corporation
Not Provided
Not Provided
Repligen Corporation
August 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP